AbbVie Inc.

• ABBV Stock Price 24h change: -1.81%. From 224.13 USD to 220.08 USD. • From a technical perspective, the stock is showing "short-term bearish consolidation" within a long-term uptrend. While ABBV remains above its 200-day moving average (204.69), it has slipped below its 20-day (227.08) and 50-day (225.91) averages. Indicators like the RSI (38.6) and MACD (-1.61) suggest selling pressure and a "Strong Sell" daily signal as it tests support near the $220 level.
• AbbVie signed an exclusive licensing deal with RemeGen to develop RC148, a novel bispecific antibody for advanced solid tumors, aiming to bolster its oncology pipeline.
• The company announced the acquisition of a manufacturing facility in Arizona for $175 million to strengthen its U.S. production capabilities and support its $10 billion long-term investment plan.
• AbbVie officially denied recent rumors regarding a potential acquisition of Revolution Medicines, leading to the removal of a speculative "takeover premium" from the stock price.
• Anthropic and OpenAI launched specialized AI health assistants (Claude for Healthcare and ChatGPT Health), signaling a major shift toward HIPAA-ready generative AI in medical data management.
• Nearly 15,000 nurses in New York City launched a major strike at several top hospitals over staffing and contract disputes, threatening to disrupt healthcare operations across the region.

• ABBV Stock Price 24h change: -1.81%. From 224.13 USD to 220.08 USD. The decline was primarily driven by the company's official denial of acquisition talks with Revolution Medicines and a $1.3 billion IPR&D charge that is expected to pressure Q4 earnings.
• From a technical perspective, ABBV exhibits a "strong sell" signal in the short term. The stock has broken below its 50-day moving average ($226.59) and its short-term support levels. While the 200-day moving average ($215.32) provides a long-term cushion, the RSI at approximately 38.6 indicates bearish momentum, suggesting the market is still digesting recent negative news and guidance adjustments.
• AbbVie officially denied media reports suggesting it was in advanced talks to acquire cancer-drug developer Revolution Medicines, causing a reversal of earlier speculative gains.
• The company flagged a $1.3 billion pre-tax charge related to acquired in-process research and development (IPR&D), leading to a lowered Q4 adjusted EPS guidance range of $2.61 - $2.65, below analyst expectations.
• Analysts at Zacks and other firms highlight that strong demand for immunology drugs Skyrizi and Rinvoq remains the core growth thesis for 2026, helping to offset the continued revenue erosion of Humira.
• President-elect Trump announced plans to meet with executives from 14 major health insurance companies to pressure them into lowering healthcare costs following the expiration of ACA tax credits.
• The S&P 500 Healthcare Index (XLV) saw significant volatility as investors rotated into defensive biosimilar plays, while major pharmaceutical companies faced renewed pressure over insulin pricing lawsuits and PBM transparency.